Ontology highlight
ABSTRACT:
SUBMITTER: Starrett JH
PROVIDER: S-EPMC7392201 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Starrett Jacqueline H JH Guernet Alexis A AA Cuomo Maria Emanuela ME Poels Kamrine E KE van Alderwerelt van Rosenburgh Iris K IK Nagelberg Amy A Farnsworth Dylan D Price Kristin S KS Khan Hina H Ashtekar Kumar Dilip KD Gaefele Mmaserame M Ayeni Deborah D Stewart Tyler F TF Kuhlmann Alexandra A Kaech Susan M SM Unni Arun M AM Homer Robert R Lockwood William W WW Michor Franziska F Goldberg Sarah B SB Lemmon Mark A MA Smith Paul D PD Cross Darren A E DAE Politi Katerina K
Cancer research 20200319 10
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for <i>EGFR</i>-mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib in transgenic mouse models of <i>EGFR<sup>L858R</sup></i> -induced lung adenocarcinoma and found that it is mediated largely through secondary mutations in <i>EGFR</i>-either C797S or L718V/Q. Analysis of circulating free DNA data from patien ...[more]